Cargando…

Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States

INTRODUCTION: Transformation of higher-risk myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) may be associated with increased healthcare resource utilization (HCRU) and costs. To describe this economic impact, HCRU and costs were compared between US patients who experienced transforma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kota, Vamsi, Ogbonnaya, Augustina, Farrelly, Eileen, Schroader, Bridgette Kanz, Raju, Aditya, Kristo, Fjoralba, Dalal, Mehul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070206/ https://www.ncbi.nlm.nih.gov/pubmed/36422807 http://dx.doi.org/10.1007/s12325-022-02370-4

Ejemplares similares

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant
por: Ailawadhi, Sikander, et al.
Publicado: (2022)

Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
por: Bell, Jill A., et al.
Publicado: (2018)

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes
por: Zeidner, Joshua F., et al.
Publicado: (2022)

The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia
por: Spargo, Andrew, et al.
Publicado: (2021)

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
por: Li, Edward, et al.
Publicado: (2021)

Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis
por: McBride, Ali, et al.
Publicado: (2021)

Acute Myeloid Leukemia with Basophilic Differentiation Transformed from Myelodysplastic Syndrome
por: Tanaka, Yasuhiro, et al.
Publicado: (2017)

Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
por: Aapro, Matti S., et al.
Publicado: (2023)

Transformation of a myelodysplastic syndrome to acute myeloid leukemia and concurrent necrotizing sweet syndrome
por: Vera-Lastra, Olga, et al.
Publicado: (2021)

Acute myeloid leukemia cells and MSC-derived exosomes inhibiting transformation in myelodysplastic syndrome
por: Liu, Xiaoli, et al.
Publicado: (2023)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
por: Oka, Satoko, et al.
Publicado: (2021)

Clostridium difficile Infection Complicated by Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia With Leukostasis and Sweet’s Syndrome
por: Landry, Ian, et al.
Publicado: (2021)

Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis
por: Raju, Aditya, et al.
Publicado: (2021)

A Rare Case of Leukemia Cutis as the First Presentation of a Myelodysplastic Syndrome to Acute Myeloid Leukemia Transformation
por: Findakly, Dawood, et al.
Publicado: (2020)

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
por: Leone, Giuseppe, et al.
Publicado: (2008)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia
por: Geyh, Stefanie, et al.
Publicado: (2018)

Myelodysplastic syndrome transforming to atypical chronic myeloid leukemia shows changes in its mutation allele frequency and acquisition of new mutations
por: NM, Hakim, et al.
Publicado: (2021)

Transformation of myelodysplastic syndrome to mixed phenotype acute leukaemia
por: Do, Louis, et al.
Publicado: (2020)

Copper deficiency mimicking myelodysplastic syndrome
por: Dalal, Neil, et al.
Publicado: (2015)

Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome
por: Huang, Huai-Hsuan, et al.
Publicado: (2019)

Myeloid sarcoma of the Gingiva with myelodysplastic syndrome: A Case Report
por: Jin, Seong-Ho, et al.
Publicado: (2016)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis
por: Langabeer, Stephen E., et al.
Publicado: (2018)

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2020)

Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Morelli, Emanuela, et al.
Publicado: (2021)

Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
por: Woll, Petter S., et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia
por: Bănescu, Claudia, et al.
Publicado: (2023)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019)

Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis
por: Ma, Jiale, et al.
Publicado: (2021)

SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis
por: NIAN, QING, et al.
Publicado: (2014)

EZH2/EHMT2 Histone Methyltransferases Inhibit the Transcription of DLX5 and Promote the Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia
por: Zheng, Zhuanzhen, et al.
Publicado: (2021)

Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
por: Sutandyo, Noorwati, et al.
Publicado: (2022)

Familial Myelodysplastic/Acute Leukemia Syndromes—Myeloid Neoplasms with Germline Predisposition
por: Baptista, Renata Lyrio Rafael, et al.
Publicado: (2017)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level
por: Chen, Jiahao, et al.
Publicado: (2018)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k3l7oqaerpsrntp40dpr8v73v6